1. Designer Gels for Cell Culture
Dr. David Lightbody, CEO

2. The Opportunity

3. A Gel for Every Cell

4. Achieving Scale
3D Cell Culture Market

5. Achieving Scale
Cell-based Assay/ Toxicity Market

6. Achieving Scale
Regenerative Medicine
Market

7. Progress so far…2013/14

8. Progress so far…2013/14

10. Investment Needs
Business Development

11. Investment Needs IP

12. Investment Needs
Operations

13. Management Accounts: to end Nov ’14
INCOME (to end Nov‘14)
Product Sales
£ 30k
R & D Contracts
(private)
£ 53k
R & D Contracts
(public)
£ 85k
TOTAL
£ 178k
COSTS (to end Nov‘14)
Cost of Sales
£ 118k
Overheads
£ 90k
TOTAL
£ 208k

14. Current Shareholders Shareholder % Equity Rein Ulijn 40%
David Lightbody
15%
Douglas Hutchison 5%
University of Strathclyde
20%
Gabriel
10%
SIB

15. Draft Projections: ’15 – ’19 (£’000’s)
2015
2016
2017
2018
2019
Sales (£k)
386
1,300
2,265
3,485
5,055
Gross Profit (£k)
166
586
1,111
1,810
2,777
Gross Margin (%) 43 51 54 64 55
EBITDA (£k)
(79)
(14)
339
869
1,730
Net Assets (£k)
(32)
(72)
171
790
2,090
Funding Requirement (£k)
(500)

16. Academic to Commercial
Success to date:
Academic to Commercial
International Sales
New IP